Leading Companies Fueling Growth and Innovation in the Biosimilar Contract Manufacturing Market

The biosimilar contract manufacturing sector is set to experience significant expansion in the coming years, driven by advancements and increasing demand within the biopharmaceutical industry. This report explores the market's current size, key players, prevailing trends, and detailed segmentation, offering a comprehensive view of what lies ahead for this rapidly evolving field.

Projected Growth and Size of the Biosimilar Contract Manufacturing Market
The biosimilar contract manufacturing market is poised for swift growth, expected to reach a valuation of $20.35 billion by 2030. This represents a compound annual growth rate (CAGR) of 15.4%. The surge during the forecast period can be linked to several factors, including a rising number of biosimilar approvals worldwide, mounting pressure to reduce the cost of biologic therapies, the expansion of biosimilar development pipelines, increased investments in large-scale manufacturing capabilities, and ongoing improvements in process optimization technologies. Prominent trends shaping the market include a growing shift toward outsourcing biosimilar production, demand for more cost-effective manufacturing platforms, heightened focus on analytical and quality control services, expansion of mammalian cell-based manufacturing methods, and stronger regulatory compliance measures.

Download a free sample of the biosimilar contract manufacturing market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Primary Companies Driving the Biosimilar Contract Manufacturing Industry
Several key organizations are leading the biosimilar contract manufacturing space, including:
Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., and Polpharma Biologics S.A.

Strategic Acquisition Enhancing Market Position
In a notable move in October 2023, US-based private equity firms Advent International Corporation and Warburg Pincus LLC acquired BioPharma Solutions' business, now known as Simtra BioPharma Solutions, from Baxter International Inc. Although the deal amount was not disclosed, this acquisition aims to strengthen their foothold in the biopharmaceutical manufacturing sector by leveraging BioPharma Solutions' expertise in contract development and manufacturing of biologics and biosimilars. Baxter International Inc., meanwhile, continues to be recognized as a prominent biotechnology company providing biosimilar contract manufacturing services.

View the full biosimilar contract manufacturing market report:
https://www.thebusinessresearchcompany.com/report/global-biosimilar-contract-manufacturing-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Innovative Trends Shaping the Future of Biosimilar Contract Manufacturing
Leading companies in the biosimilar contract manufacturing arena are increasingly investing in new production models such as mirrored single-use plants to speed up technology transfer, scale-up processes, and ensure consistent commercial quality. These mirrored single-use plants feature identical production suites equipped with disposable bioprocess equipment and unified digital systems. This setup allows quick changeovers, uniform product quality across different sites, and reduced contamination risk.

For example, in September 2025, Rezon Bio, a Poland-based CDMO, inaugurated two mirrored single-use biomanufacturing facilities covering all stages from cell line development to commercial GMP supply. This innovative approach enables faster tech transfer and scalable manufacturing for biosimilars with minimal downtime. It also improves batch consistency through standardized processes, integrated analytics, and automated logistics. Additionally, it reduces total ownership costs for sponsors by cutting down cleaning validation requirements, shortening manufacturing timelines, and lowering expansion risks.

Detailed Segment Breakdown of the Biosimilar Contract Manufacturing Market
The report categorizes the biosimilar contract manufacturing market into multiple segments:

1) Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, and Other Product Types
2) Service Type: Process Development, Analytical and Quality Control, Fill and Finish Operations, Packaging, and Other Services
3) Source: Mammalian and Non-mammalian
4) Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, and Other Applications
5) End-Use: Pharmaceutical Companies and Biotech Companies

Further subcategories include:
- Monoclonal Antibodies: Chimeric, Humanized, Fully Human, and Bispecific types
- Insulin: Rapid-acting, Short-acting, Intermediate-acting, Long-acting, and Premixed variants
- Erythropoietin: Alpha, Beta, Darbepoetin Alfa, and Continuous Erythropoietin Receptor Activators
- Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, and Long-acting forms
- Other product types include Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, and Hormonal Biologics.

This comprehensive segmentation provides a nuanced understanding of the market's structure and the diverse product and service offerings shaping its development.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.